 |
2 Diseases |  |
32 Trials |
|
32 Trials |  |
1662 News |  |
| «12...1213141516171819202122...2425» |
- |||| Prevymis (letermovir) / Merck (MSD)
Clinical: Our CIBMTR analysis coming out soon in Blood (accepted paper) showing higher CMV reactivation in haplos,, so makes perfect sense to add letermovir to all at risk haplo patients. (Twitter) - Mar 4, 2021
- |||| Prevymis (letermovir) / Merck (MSD)
Clinical: #Letermovir Prophylaxis for #cmv was particularly beneficial for #haploidentical #HCT patients in the phase 3 trial. The #cibmtr analysis goes to through 2017. Will be cool to look again soon. .@romeerizwan .@JessicaLittleMD .@drkomanduri .@BldCancerDoc https://t.co/rGICrTjFHk (Twitter) - Mar 4, 2021
- |||| Prevymis (letermovir) / Merck (MSD)
Trial completion date, Trial primary completion date: Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002) (clinicaltrials.gov) - Mar 4, 2021
P3, N=600, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Aug 2022 --> May 2022 | Trial primary completion date: Aug 2022 --> May 2022
- || Prevymis (letermovir) / Merck (MSD)
Gabe, I think you'd be hard pressed to find anyone starting letermovir w an incr VL I'm saying that bc you had it as an option in your choices. I would not have started anything w a VL 400 , but probably around 1500 and decr some IS. Agee w IHC stain for colo. (Twitter) - Mar 3, 2021
- || Prevymis (letermovir) / Merck (MSD)
still not a significant jump, but concerning. UL56 mutation is possible (can send for this to know if usable in the future) esp if letermovir missed around surgery or po absorption questionable given critical illness. You will eventually have to give GCV while you sort things out (Twitter) - Mar 3, 2021
- || Prevymis (letermovir) / Merck (MSD), Campath (alemtuzumab) / Sanofi
Enrollment open: Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab (clinicaltrials.gov) - Mar 3, 2021
P2, N=30, Recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Trial completion date: Aug 2022 --> May 2022 | Trial primary completion date: Aug 2022 --> May 2022 Not yet recruiting --> Recruiting
- | Prevymis (letermovir) / Merck (MSD), Vocozo (voriconazole) / Orchid
Observational data, Retrospective data, Journal: Tacrolimus Concentration after Letermovir Initiation in Hematopoietic Stem Cell Transplantation Recipients Receiving Voriconazole: A Retrospective, Observational Study. (Pubmed Central) - Feb 25, 2021
This can be explained by the increase in TAC concentration caused by CYP3A4 inhibition due to LMV and by the decrease in TAC concentration ascribed to the decrease in VRCZ concentration by CYP2C19 induction due to LMV. These results suggest that it is unnecessary to adjust the dose of TAC based on LMV initiation; however, it is necessary to adjust the dose of TAC based on conventional TAC concentration measurements.
- |||||| Prevymis (letermovir) / Merck (MSD), maribavir (TAK-620) / Takeda, GSK
Late-breaking abstract: #TCTM21 CMV in HSCT: Refractory CMV ✔️Only 10% w/ resistance mutations ✔️After 2 weeks, risk of resistance 50% ✔️Role of Maribavir (➡️ LBA) ✔️Letermovir and maribavir specific for human CMV ✔️Zoster may not be covered depending on agent @FranciscoMarty_ @DanaFarber @ASTCT (Twitter) - Feb 11, 2021
- || Prevymis (letermovir) / Merck (MSD)
After listening to talk at edn session, focused on the non Signiant but greater risk of infections. 71 % vs 60% in the PTCY vs std arm.. the authors used letermovir (Twitter) - Feb 8, 2021
- | Prevymis (letermovir) / Merck (MSD)
Journal, Heterogeneity: De Novo Genotypic Heterogeneity in the UL56 Region in Cytomegalovirus-infected Tissues: Implications for Primary Letermovir Resistance. (Pubmed Central) - Feb 5, 2021
These results suggest that it is unnecessary to adjust the dose of TAC based on LMV initiation; however, it is necessary to adjust the dose of TAC based on conventional TAC concentration measurements. The treatment difficulties associated with letermovir resistance in a clinical setting need to be verified prior to its widespread use.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] THE IMPACT OF LETERMOVIR PRESCRIBING ON THE RATE OF CYTOMEGALOVIRUS REACTIVATION FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_3219;
Letermovir prophylaxis reduced CMV reactivation, treatment requirement and hospitalisation up to day+168 post-transplant but increased overall expenditure. Further studies are needed to assess optimal duration of letermovir therapy and impact on quality of life.
- [VIRTUAL] EPIDEMIOLOGY OF RESISTANT AND REFRACTORY CYTOMEGALOVIRUS INFECTION FOLLOWING SOLID ORGAN OR HAEMATOPOIETIC STEM CELL TRANSPLANT: A SYSTEMATIC REVIEW (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2902;
However, estimates in SOT recipients in Europe and the USA were heterogeneous; for HSCT recipients, there was a lack of observational data from Europe. While there is limited recent data on refractory CMV infection in transplant recipients in both Europe and the USA, this review may provide insights in quantifying the potential number of patients eligible for emerging therapies for resistant or refractory CMV infection.
- [VIRTUAL] EPIDEMIOLOGY OF RESISTANT AND REFRACTORY CYTOMEGALOVIRUS INFECTION FOLLOWING SOLID ORGAN OR HAEMATOPOIETIC STEM CELL TRANSPLANT: A SYSTEMATIC REVIEW (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2901;
However, estimates in SOT recipients in Europe and the USA were heterogeneous; for HSCT recipients, there was a lack of observational data from Europe. While there is limited recent data on refractory CMV infection in transplant recipients in both Europe and the USA, this review may provide insights in quantifying the potential number of patients eligible for emerging therapies for resistant or refractory CMV infection.
- [VIRTUAL] EPIDEMIOLOGY OF RESISTANT AND REFRACTORY CYTOMEGALOVIRUS INFECTION FOLLOWING SOLID ORGAN OR HAEMATOPOIETIC STEM CELL TRANSPLANT: A SYSTEMATIC REVIEW (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2900;
However, estimates in SOT recipients in Europe and the USA were heterogeneous; for HSCT recipients, there was a lack of observational data from Europe. While there is limited recent data on refractory CMV infection in transplant recipients in both Europe and the USA, this review may provide insights in quantifying the potential number of patients eligible for emerging therapies for resistant or refractory CMV infection.
- [VIRTUAL] EPIDEMIOLOGY OF RESISTANT AND REFRACTORY CYTOMEGALOVIRUS INFECTION FOLLOWING SOLID ORGAN OR HAEMATOPOIETIC STEM CELL TRANSPLANT: A SYSTEMATIC REVIEW (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2899;
However, estimates in SOT recipients in Europe and the USA were heterogeneous; for HSCT recipients, there was a lack of observational data from Europe. While there is limited recent data on refractory CMV infection in transplant recipients in both Europe and the USA, this review may provide insights in quantifying the potential number of patients eligible for emerging therapies for resistant or refractory CMV infection.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] COMPARISON BETWEEN PRIMARY PROPHYLAXIS AND PRE-EMPTIVE THERAPY FOR CITOMEGALOVIRUS AFTER HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2894;
Our experience demonstrated the efficacy of Letermovir in a real-world setting for CMV prevention in the first 14 weeks after HSCT. Further studies are needed to establish the cost-effectiveness of Letermovir primary prophylaxis compared to PET approach, and the role of extension of Letermovir beyond day +100 in high-risk subgroup.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] COMPARISON BETWEEN PRIMARY PROPHYLAXIS AND PRE-EMPTIVE THERAPY FOR CITOMEGALOVIRUS AFTER HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2893;
Our experience demonstrated the efficacy of Letermovir in a real-world setting for CMV prevention in the first 14 weeks after HSCT. Further studies are needed to establish the cost-effectiveness of Letermovir primary prophylaxis compared to PET approach, and the role of extension of Letermovir beyond day +100 in high-risk subgroup.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] COMPARISON BETWEEN PRIMARY PROPHYLAXIS AND PRE-EMPTIVE THERAPY FOR CITOMEGALOVIRUS AFTER HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2892;
Our experience demonstrated the efficacy of Letermovir in a real-world setting for CMV prevention in the first 14 weeks after HSCT. Further studies are needed to establish the cost-effectiveness of Letermovir primary prophylaxis compared to PET approach, and the role of extension of Letermovir beyond day +100 in high-risk subgroup.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] COMPARISON BETWEEN PRIMARY PROPHYLAXIS AND PRE-EMPTIVE THERAPY FOR CITOMEGALOVIRUS AFTER HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2891;
Our experience demonstrated the efficacy of Letermovir in a real-world setting for CMV prevention in the first 14 weeks after HSCT. Further studies are needed to establish the cost-effectiveness of Letermovir primary prophylaxis compared to PET approach, and the role of extension of Letermovir beyond day +100 in high-risk subgroup.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] LETERMOVIR PROPHYLAXIS REDUCES THE RISK FOR CMV INFECTION AFTER STEM CELL TRANSPLANTATION (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2719;
The use of letermovir prophylaxis is associated with a significant lower risk of CMV infections after allogeneic stem cell transplantation. Furthermore, we did not see any toxicity in terms of leucocyte and platelet engraftment as well as overall survival.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] LETERMOVIR PROPHYLAXIS REDUCES THE RISK FOR CMV INFECTION AFTER STEM CELL TRANSPLANTATION (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2718;
The use of letermovir prophylaxis is associated with a significant lower risk of CMV infections after allogeneic stem cell transplantation. Furthermore, we did not see any toxicity in terms of leucocyte and platelet engraftment as well as overall survival.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] LETERMOVIR PROPHYLAXIS REDUCES THE RISK FOR CMV INFECTION AFTER STEM CELL TRANSPLANTATION (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2717;
The use of letermovir prophylaxis is associated with a significant lower risk of CMV infections after allogeneic stem cell transplantation. Furthermore, we did not see any toxicity in terms of leucocyte and platelet engraftment as well as overall survival.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] LETERMOVIR PROPHYLAXIS REDUCES THE RISK FOR CMV INFECTION AFTER STEM CELL TRANSPLANTATION (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2716;
The use of letermovir prophylaxis is associated with a significant lower risk of CMV infections after allogeneic stem cell transplantation. Furthermore, we did not see any toxicity in terms of leucocyte and platelet engraftment as well as overall survival.
- cyclosporine / Generic mfg.
[VIRTUAL] TRIPLE PTCY BASED GVHD PROPHYLAXIS: HLA MATCHED VERSUS HLA HAPLOIDENTICAL TRANSPLANTS (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2647;
This translates in significantly reduced TRM. However, relapse appears to be increased, particularly in advanced diseases, leading to identical disease free survival.
- cyclosporine / Generic mfg.
[VIRTUAL] TRIPLE PTCY BASED GVHD PROPHYLAXIS: HLA MATCHED VERSUS HLA HAPLOIDENTICAL TRANSPLANTS (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2646;
This translates in significantly reduced TRM. However, relapse appears to be increased, particularly in advanced diseases, leading to identical disease free survival.
- cyclosporine / Generic mfg.
[VIRTUAL] TRIPLE PTCY BASED GVHD PROPHYLAXIS: HLA MATCHED VERSUS HLA HAPLOIDENTICAL TRANSPLANTS (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2645;
This translates in significantly reduced TRM. However, relapse appears to be increased, particularly in advanced diseases, leading to identical disease free survival.
- cyclosporine / Generic mfg.
[VIRTUAL] TRIPLE PTCY BASED GVHD PROPHYLAXIS: HLA MATCHED VERSUS HLA HAPLOIDENTICAL TRANSPLANTS (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2644;
This translates in significantly reduced TRM. However, relapse appears to be increased, particularly in advanced diseases, leading to identical disease free survival.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS REACTIVATION IN ALLOGENEIC STEM CELL TRANSPLANTATION: A MULTICENTER ITALIAN REAL-WORLD EXPERIENCE (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1836;
Letermovir confirmed its efficacy in preventing CMV infection in the first 100 days after HSCT in a real-world population analysis. An extension of prophylaxis of up to 200 days should be considered, and clinical trials to this end are expected.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS REACTIVATION IN ALLOGENEIC STEM CELL TRANSPLANTATION: A MULTICENTER ITALIAN REAL-WORLD EXPERIENCE (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1835;
Letermovir confirmed its efficacy in preventing CMV infection in the first 100 days after HSCT in a real-world population analysis. An extension of prophylaxis of up to 200 days should be considered, and clinical trials to this end are expected.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS REACTIVATION IN ALLOGENEIC STEM CELL TRANSPLANTATION: A MULTICENTER ITALIAN REAL-WORLD EXPERIENCE (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1834;
Letermovir confirmed its efficacy in preventing CMV infection in the first 100 days after HSCT in a real-world population analysis. An extension of prophylaxis of up to 200 days should be considered, and clinical trials to this end are expected.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS REACTIVATION IN ALLOGENEIC STEM CELL TRANSPLANTATION: A MULTICENTER ITALIAN REAL-WORLD EXPERIENCE (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1833;
Letermovir confirmed its efficacy in preventing CMV infection in the first 100 days after HSCT in a real-world population analysis. An extension of prophylaxis of up to 200 days should be considered, and clinical trials to this end are expected.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] IMMUNE RECONSTITUTION DURING CMV PROPHILAXIS BY LETERMOVIR: A SINGLE CENTER EXPERIENCE (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1832;
LET seems to promote a better immune recovery after HSCT especially for CD3+CD8+ lymphocytes. The protective role of CD3+CD8+lymphocytes against CMV reactivation has already been described as well as the role of CD4+/CD8+ ratio and CD3+CD4+.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] IMMUNE RECONSTITUTION DURING CMV PROPHILAXIS BY LETERMOVIR: A SINGLE CENTER EXPERIENCE (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1831;
LET seems to promote a better immune recovery after HSCT especially for CD3+CD8+ lymphocytes. The protective role of CD3+CD8+lymphocytes against CMV reactivation has already been described as well as the role of CD4+/CD8+ ratio and CD3+CD4+.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] IMMUNE RECONSTITUTION DURING CMV PROPHILAXIS BY LETERMOVIR: A SINGLE CENTER EXPERIENCE (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1830;
LET seems to promote a better immune recovery after HSCT especially for CD3+CD8+ lymphocytes. The protective role of CD3+CD8+lymphocytes against CMV reactivation has already been described as well as the role of CD4+/CD8+ ratio and CD3+CD4+.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] IMMUNE RECONSTITUTION DURING CMV PROPHILAXIS BY LETERMOVIR: A SINGLE CENTER EXPERIENCE (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1829;
LET seems to promote a better immune recovery after HSCT especially for CD3+CD8+ lymphocytes. The protective role of CD3+CD8+lymphocytes against CMV reactivation has already been described as well as the role of CD4+/CD8+ ratio and CD3+CD4+.
- | Journal: Advances in the Development of Therapeutics for Cytomegalovirus Infections. (Pubmed Central) - Feb 2, 2021
First, the deployment of ganciclovir and valganciclovir for both the prevention and treatment of CMV infections and disease in transplant recipients has been further improved with the licensure of the efficacious and less toxic letermovir...Thus, an important lesson learned from studies in both populations is the need for new antiviral agents and the necessity for combination therapies as has been shown to be beneficial in the treatment of HIV infections, among others. The development of monoclonal antibodies, sirtuins, and cyclopropovir may provide new treatment options.
- | Prevymis (letermovir) / Merck (MSD), Livtencity (maribavir) / Takeda, GSK
Journal: Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence. (Pubmed Central) - Feb 2, 2021
We also explore the role of donor factors in transmitting CMV after SOT. Finally, we propose a framework with which to approach CMV prevention in the foreseeable future.
- | Prevymis (letermovir) / Merck (MSD)
New trial: Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Randomized Against Valaciclovir - STEP 1 (CYMEVAL3-STEP1) (clinicaltrials.gov) - Feb 1, 2021
P=N/A, N=10, Not yet recruiting, Sponsor: Assistance Publique - H
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] COST-EFFECTIVENESS OF LETERMOVIR AS CMV PROPHYLAXIS IN ADULT ALLO-HSCT RECIPIENTS IN HONG KONG () - Jan 30, 2021 - Abstract #APBMT2020APBMT_44;
Finally, we propose a framework with which to approach CMV prevention in the foreseeable future. Letermovir prophylaxis would be cost-effective for preventing CMV infection in adult seropositive allogeneic HSCT recipients in Hong Kong.
- || Prevymis (letermovir) / Merck (MSD)
And letermovir prophylaxis to go along 😉 (Twitter) - Jan 21, 2021
- | Prevymis (letermovir) / Merck (MSD)
Journal: Management of cytomegalovirus infection after hematopoietic stem cell transplantation (Pubmed Central) - Jan 21, 2021
In the future, it is expected that survival after allogeneic HSCT will be improved by preventing CMV infection. However, further investigations are warranted to solve problems, such as the establishment of the appropriate prophylaxis for CMV infection and the management of late-onset and drug-resistant CMV infection.
- || Prevymis (letermovir) / Merck (MSD), maribavir (TAK-620) / Takeda, GSK
Review, Journal: Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Pubmed Central) - Jan 13, 2021
Issues of standardization and diagnostic utility in comparison with traditional Sanger sequencing remain unresolved. Quality control is important for the accurate and reproducible detection of mutant viral populations in clinical specimens.
- || Vistide (cidofovir) / Gilead, filociclovir (MBX400) / Microbiotix
Review, Journal: The discovery and development of filociclovir for the prevention and treatment of human cytomegalovirus-related disease. (Pubmed Central) - Jan 13, 2021
The most recently approved drug, letermovir (LMV), was approved only for prophylaxis in adult HCMV-seropositive stem cell transplant recipients...Furthermore, FCV was shown to retain activity against a panel of GCV-resistant HCMV isolates, suggesting that it could be a useful alternative therapy for treating patients infected with some GCV-resistant HCMV strains. This review summarizes the early discovery work of FCV and highlights the recent advances in the continued development of this clinical candidate.
- || Prevymis (letermovir) / Merck (MSD)
Review, Journal: The direct and indirect consequences of cytomegalovirus infection and potential benefits of vaccination. (Pubmed Central) - Jan 13, 2021
This article describes the studies that have been conducted to date and emphasises that mortality after stem cell transplant (not attributed to CMV end-organ disease) has recently become the first proven indirect effect of CMV now that letermovir has significantly reduced non-relapse deaths...A prototype scheme for assessing this possibility is provided in order to stimulate discussion within the field. This article forms part of an online symposium on the prevention and therapy of DNA virus infections, dedicated to the memory of Mark Prichard.
- ||| Prevymis (letermovir) / Merck (MSD)
Clinical: Not to mention the DDIs with letermovir which is used in exactly the population this analysis recommends using vori. (Twitter) - Jan 12, 2021
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Letermovir Vs High Dose Valacyclovir for Cytomegalovirus Prophylaxis Following Haploidentical Allogeneic Hematopoietic Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2902;
Breakthrough viremia occurred later with LET. Study limitations include modest cohort size, limited follow-up, and inability to assess compliance.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Letermovir Vs High Dose Valacyclovir for Cytomegalovirus Prophylaxis Following Haploidentical Allogeneic Hematopoietic Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2901;
Breakthrough viremia occurred later with LET. Study limitations include modest cohort size, limited follow-up, and inability to assess compliance.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Letermovir Vs High Dose Valacyclovir for Cytomegalovirus Prophylaxis Following Haploidentical Allogeneic Hematopoietic Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2900;
Breakthrough viremia occurred later with LET. Study limitations include modest cohort size, limited follow-up, and inability to assess compliance.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Letermovir Vs High Dose Valacyclovir for Cytomegalovirus Prophylaxis Following Haploidentical Allogeneic Hematopoietic Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2899;
Breakthrough viremia occurred later with LET. Study limitations include modest cohort size, limited follow-up, and inability to assess compliance.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Letermovir Vs High Dose Valacyclovir for Cytomegalovirus Prophylaxis Following Haploidentical Allogeneic Hematopoietic Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2898;
Breakthrough viremia occurred later with LET. Study limitations include modest cohort size, limited follow-up, and inability to assess compliance.